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ABSTRACT:  
Background:  Cholinesterase  inhibitory  therapy  serves  as  a  strategy  for  the  treatment  of 
Alzheimer’s  disease  (AD).  Several  acetylcholinesterase  inhibitors  (AChEIs)  are  used  for  the 
symptomatic treatment of AD. These compounds have been reported to have adverse effects, 
including gastrointestinal disturbances. 
This study was therefore partly aimed at investigating in vitro possible AChEIs in herbal 
medicines traditionally used in Palestine to treat cognitive disorders, and to point out the role of 
these plants as potential sources for development of newly potent and safe natural therapeutic 
agents of AD. Assay of AChE activity plays an important role in vitro characterization of drugs 
including potential treatments  for AD. The most  widely used method, is  based on Ellman’s 
method. The reactant used in this method shows chemical reactivity with oxime antidots and 
thiol leading to false positive reactions. A new alternative assay could be of high interest. 
 
Methods: The effect on AChE activity of 92 extracts of 47 medicinal plants were evaluated 
using  a  new  micro-well  plate  AChE  activity  (NA-FB)  and    Ellman’s  assays.    In  addition, 
antioxidant activity using DPPH was determined. 
 
Results: The main advantages of the new method (NA-FB) is that the colorimetric change is 
better observable visually allowing spectrophotometric as well as colorimetric assay, and does 
not show any chemical reactivity with thiol. 67.4% and 37% of extracts inhibited AChE by 
>50% using the NA-FB and Ellman’s  assays,  respectively. Using NA-FB assay,  84 extracts 
interacted reversibly with the enzyme, of which Mentha spicata (94.8%), Foeniculum vulgare 
(89.81), and Oxalis pes-caprae (89.21) were most potent, and 8 showed irreversible inhibition of Functional Foods in Health and Disease 2014; 4(9):381-400                                                            Page 382 of 400 
which  leaves  of  Lupinus  pilosus  (92.02%)  were  most  active.  Antioxidant  activity  was 
demonstrated by  73  extracts  Majorana  syriaca  (IC50  0.21mg/ml),  and  Rosmarinus  officinalis 
(0.38) were the most active.    
 
Conclusions: NA-FB assay has shown to be simple, accurate, sensitive, spectrophotometric and 
colorimetric, and superior to Ellman’s, and therefore can be used efficiently for qualitative and 
quantitative studies of AChEI activities of extracts. Palestinian flora have shown to be a rich 
source for, new and promising agents (AChEIs) for the treatment of AD  Further studies are 
needed to isolate and identify the active compounds responsible for AChEI activities. 
 
Keywords: Alzheimer's disease, ACh, medicinal plants,  β-naphthyl acetate, micro-well plate 
AChE activity Assay (NA-FB) 
 
 
BACKGROUND:  
Numerous medicinal plants have been used in Traditional Arabic Palestinian Herbal Medicine 
(TAPHM) for the treatment of several diseases, including improvement of memory, Alzheimer’s 
disease (AD) and old age related diseases [1, 2]. However, the use of medicinal plants is mainly 
based on local tradition and not scientific knowledge. 
AD  is  the  most  common  form  of  dementia  that  affects  more  than  35  million  people 
worldwide and this number is believed to reach 65.7 million by 2030 [3]. It is one of the most 
widespread  neurodegenerative  disorders  that  results  in  progressive  loss  of  memory  and 
cognition, and deterioration of virtually all intellectual functions  [3, 4].  AD has become the 
fourth leading cause of death in the elderly population (over 65 years of age) as a result of 
different biochemical pathways [5, 6]. The number of people with AD is expected to increase 
substantially in the coming years as the proportion of the population aged 65 years or more rises 
sharply [7].  
A loss of acetylcholine (ACh) is considered to play a vital role in the learning and memory 
deterioration of AD patients. Acetylcholine is an organic molecule released at nerve endings as a 
neurotransmitter. It is produced by choline acetyltransferase which uses acetyl coenzyme-A and 
choline as substrates for the formation of acetylcholine in specific cells known as cholinergic 
neurons.  Neurotransmitter  disturbances  and  insufficient  cholinergic  functions  are  identified 
among the pathological features in central nervous system disorders [8]. 
There are several strategies to improve cholinergic neurotransmission[9], although the one 
that  has  been  most  successful  so  far  is  the  “cholinergic  hypothesis”,  i.e.,  stimulation  of 
cholinergic receptors or increasing the availability of ACh released into the neuronal synaptic 
cleft  by  inhibiting  ACh  hydrolysis  by  acetylcholinesterase  (AChE)  through  the  use  AChE 
inhibitors (AChEIs) [10, 11]. AChE is a membrane-bound enzyme found in excitable tissues, 
such  as  synaptic  junctions.  The  principle  role  of  AChE  is  the  termination  of nerve impulse 
transmission at the cholinergic synapses by rapid hydrolysis of the neurotransmitter ACh [12]. 
Thus, AChEIs (e.g., the drugs used for the AD therapy) promote an increase in the concentration 
and duration of action of synaptic ACh [13, 14]. The therapy of early and moderate AD is 
therefore mainly based on AChEIs such as synthetic galanthamine and donepezil isolated from Functional Foods in Health and Disease 2014; 4(9):381-400                                                            Page 383 of 400 
the bulbs of daffodils [15]. However, these drugs are known to have limitations due to their 
short-half-lives  and/or  unfavorable  side  effects  (including  gastrointestinal  disturbances)  and 
problems associated with bioavailability [16-18], which necessitates the interest in finding better 
AChEIs from natural resources [19-24]. 
In traditional practices of medicine, including TAPHM, plants have been used to enhance 
cognitive function and to reduce other symptoms associated with AD [2, 12]. The search for 
plant derived AChEI’s has accelerated in view of the benefits of these drugs in the treatment of 
AD  and  other  forms  of  dementia  [25,  26].  Along  with  the  prototype  inhibitor  of  AChE 
physostigmine, derived from the plant Phytostigma vevenosum, other molecules with high anti-
cholinesterase  activity  include  galantamine,  huperzine-A,  alpha-viniferin  and  ursolic  acid 
obtained from Galanthus nivalis and Narcissus sp., Huperzia serrata, Caragana chamlague and 
Origanum majorana, respectively. 
Many synthetic anticholinesterase drugs take their origin from plant-derived substances and 
belong to a diversity of classes of compounds and structures. The majority of these bioactive 
substances  are  indole-,  steroidal-,  piperidine-  and  Amaryllidaceae  alkaloids,  glycosides, 
coumarins,  phenylpropanoids  and  terpenoids  [12].  Since  AD,  the  fourth  cause  of  death 
worldwide, has become a threat to public health, new treatment strategies based on medicinal 
plants have become focused.  
In addition, strong experimental evidences have indicated that reactive oxygen species are 
associated with the pathogenesis of AD, as some cellular characteristics of this disease are either 
causes or effects of oxidative stress theory (refers to the physiological condition at which the 
capacity of the endogenous antioxidant system fails to cope with the damaging effects of free 
radicals)  of  AD  pathogenesis  [27-30].  Generally,  the  physiological  role  of  antioxidant 
compounds is to attenuate the oxidation chain reactions by removing free-radical intermediates 
[28].  Since  strong  experimental  evidences  demonstrate  that  oxidative  stress  is  intimately 
involved in age-related neurodegenerative diseases, there have been a number of studies which 
have  examined  the  positive  effects  of  antioxidants  in  reducing  or  blocking  neuronal  death 
occurring in the pathophysiology of these disorders [31]. Consequently, the use of antioxidants 
has been explored in an attempt to slow AD progression and neuronal degeneration [11]. 
Determination of AChE activity has become an important tool in drug design and discovery 
as well as in medicine and toxicology. A broad variety of methods have been developed over the 
past decades for AChE inhibitory activity quantification [5, 32, 33].  The most common assay is 
based on Ellman’s method [34] using the substrate acetylthiocholine iodide (ACTI) and 5,5’-
dithio-bis-2-nitrobenzoic  acid  (DTNB).  The  method  is  still  used,  generally  with  significant 
modifications [35]. It has some disadvantages, including large interference of some compounds. 
This method is particularly limited for testing antidots against organophosphorus AChEIs, or for 
measuring AChE activity in samples of such treated individuals. The antidots contain reactive 
oxime group splitting DTNB and provide false positive reaction in a process called oximolysis 
[36].  
In this work we present experiments to determine AChE activity assay using β-naphthyle 
acetate as an alternative substrate, and fast blue B salt as the color reagent (absorbance at 600 
nm), instead of DTNB. We introduced a new alternative protocol to the Ellman’s method, which 
could be of high interest when DTNB generates unwanted side reactions [37]. Functional Foods in Health and Disease 2014; 4(9):381-400                                                            Page 384 of 400 
Therefore, the aims of this study were (1) to develop an economic, accurate, reproducible, and 
convenient  colorimetric  micro-well  plate  assay  for  qualitative  as  well  as  quantitative 
spectrophotometric  analysis  of  phytochemical  ingredients  with  activity  against  AChE;  (2) 
investigate  in  vitro  possible  AChEIs  in  Palestinian  herbal  medicines  traditionally  used  in 
TAPHM, and to point out the role of these plants as potential sources for the development of 
newly potent and safe natural therapeutic agents of AD. Selection of the plants screened in this 
study was based on their use as remedies for the central nervous system diseases, as antidotes for 
human and animal poisoning or to improve memory and cognitive function.  
 
METHODS: 
Reagents and Chemicals 
Acetylcholinesterase    (AChE)  type  VI-S  from  an  electric  eel,  Tris-HCl  Tris(hydroxymethyl) 
aminomethane  hydrochloride],  β-naphtyl  acetate,  bovine  serum  albumin  (BSA),  3,3’-
dimethoxybiphenyl-4,4’-di(diazonium) zinc chloride (fast blue B salt), acetylthiocholine iodide  
(ATCI),    5,5´-dithiobis  [2-  nitrobenzoic  acid]  (DTNB),  galanthamine  hydrobromide,  2,2-
diphenyl-1-picrylhydrazyl (DPPH),Gallic acid, butylated hydroxyanisole (BHA), ascorbic acid  
were purchased from Sigma-Aldrich. 
 
Plant Materials and Samples Preparation 
Forty seven plant species were collected during 2014 from Nablus and Tulkarm districts in the 
Northern  part  of  Palestine  (West  Bank),  mainly  from  their  natural  habitats  or  rarely  from 
“Attarin” shops. Voucher specimens (Table 1) were deposited at the Herbarium of Biodiversity 
&  Environmental  Research  Center-BERC,  Nablus,  Palestine.  A  total  of  92  plant  parts  were 
collected and ground to fine pieces using an electric mill (Phillips, France) and plant material 
was exhaustively extracted with 60% Ethanol (2 ml/g), at room temperature for 24 hours. In all 
cases, the solutions were filtered and concentrated to dryness under reduced pressure in a rotary 
evaporator (45 ◦C). Dry extracts were stored at −20 ◦C until used. 
 
Evaluation of AChE Inhibitory Activity Using Ellman’s Method 
Inhibition of AChE activity was measured using a 96-well microplate reader (Biotek USA) based 
on Ellman’s method [34]. The chemical principle of the reaction is depicted in Figure 1. The 
enzyme hydrolyzes the substrate ATCI to thiocholine and acetic acid. Thiocholine is allowed to 
react with DTNB, and this reaction resulted in the development of a yellow color. The color 
intensity of the product is measured at 405 nm, and it is proportional to the enzyme activity.  
In the 96-well plates, a reaction mixture of 25 µl of 15 mM ATCI in water, 125 µl of 3 mM 
DTNB in buffer B and 25 µl of the plant extract were added, and the absorbance was measured 
at 405 nm. Thereafter, 25 µl of AChE solution (0.22 U/ml) was added to the wells and the 
microplate was read again at the same wavelength 10 times with 1 min intervals. Galanthamine 
dissolved in methanol was used as standard drug at 1 mg/ml concentrations; a blank of methanol 
in 50 mM Tris-HCl, (pH 8) was used. The percentage inhibition for each test solution was then 
calculated using the following equation: 
 
Inhibition (%) = 1- (Asample/Acontrol) X 100 Functional Foods in Health and Disease 2014; 4(9):381-400                                                            Page 385 of 400 
Where Asample is the absorbance of the sample extracts and Acontrol is the absorbance of the 
blank.  
 
 
Figure 1. Chemical mechanism of Ellman’s method  
 
Evaluation of AChE Inhibitory Activity Using a New Micro-Well Plate AChE Inhibition 
Assay (NA-FB) 
Taking into consideration the relative characteristics of various methods which might be useful 
in studying the AChE activity in plant extracts, led us to develop a new colorimetric assay to 
evaluate the activity of AChE, using β-naphthyl acetate as the substrate, and fast blue B salt as 
the color reagent instead of DTNB. The reaction principle is depicted in Figure 2.The enzyme 
hydrolyzes the substrate β-naphthyl acetate to naphthol and acetate. Naphthol is allowed to react 
with fast blue B. This reaction resulted in the development of a stable purple color. The color 
intensity of the product was estimated either visually, which allowed qualitative detection of the 
enzyme  inhibition,  or  was  measured  by  UV  spectrophotometer,  which  allowed  quantitative 
detection  of  the  enzyme  inhibition.  The  experiment  was  organized  as  a  common 
spectrophotometric  test  using  96-microwell  plats.  In  each  well,  10  ul  plant  extract,  50  ul 
(0.25mg/ml) of β-naphthyl acetate dissolved in methanol, and 200 µl of AChE solution (3.33 
U/ml) were added, the mixture was incubated at 4
oC for 40 min. Later, 10 ul (2.5mg/ml) fast 
blue b dissolved in water were added to the mixture and the absorbance was measured at 600 nm. 
To overcome the error in absorbance reading as a result of the plant extract color, the absorbance 
readings before incubation were subtracted from the absorbance after the addition of the dye. 
The percentage of inhibition for each test solution was calculated as mentioned above.  Functional Foods in Health and Disease 2014; 4(9):381-400                                                            Page 386 of 400 
 
 
Figure 2. AChE activity Assay using β-naphtyl acetate and fast blue B salt (NA-FB). 
 
Qualitative Determination of AChE Inhibitory Activity 
The newly modified method using β-naphthyle acetate as a substrate and fast blue B salt as color 
reagent resulted in the production of a purple color from the reaction between naphthyle and the 
reagent. However, a scale of 0-3 was used to evaluate qualitatively the inhibition of AChE by 
plant extracts: (0) No inhibition activity, solution color dark purple (as the negative control); (1) 
Mild  inhibition activity – solution color purple; (2) Moderate inhibition activity –solution color 
light purple; (3) Strong inhibition activity – no change in solution color (as the positive control).  
 
Estimation of IC50 values 
The IC50 values (concentration of test compounds that inhibits the hydrolysis of substrates by 50 
%)  were  determined  by  spectrophotometric  measurement  of  the  effect  of  increasing 
concentrations of test compounds (plant extracts and positive controls) on AChE activity. To 
calculate the IC50 values, each sample was assayed at eight concentrations (100, 50, 25, 12.5, 
6.25,  3.12,  1.56,  0.78  mg/ml).  IC50  values  were  obtained  from  dose-effect  curves  by  linear 
regression.  
 
Determination of the Inhibition Type of Plant Extracts on AChE 
The type of inhibition of AChE by extracts (reversible or irreversible inhibition) was determined 
by measuring the restored AChE activity by 10 times dilution of plant extract concentration after 
mixing and incubation of AChE and plant extract. In reversible inhibition, AChE activity was  
restored by dilution of plant extract, while there was no change in AChE activity with dilution of 
plant extract in irreversible inhibition [23]. 
 
Determination of Antioxidant Activity Using Scavenging Activity of DPPH Radical 
Free  radical  scavenging  activity  of  the  extracts  was  determined  using  the  free  radical  1,1-
diphenly-2-picrylhydrazyl-hydrate (DPPH), which is a molecule containing a stable free radical Functional Foods in Health and Disease 2014; 4(9):381-400                                                            Page 387 of 400 
[38]. In the presence of an antioxidant which can donate an electron to DPPH, the purple color 
which  is  typical  for  free  DPPH  radical  decays  and  the  change  in  absorbance  at  517  nm  is 
followed  spectrophotometerically.  The  effect  of  the  plant  extracts  on  DPPH  radical  was 
estimated using the method of Liyana-Pathirana and Shahidi [39] with minor modification. Twenty 
five micro liter of plant extract were added to 175µl of 0.004% DPPH methanolic solution, in a 
96-well plate. Appropriate blanks were prepared using the solvent only in addition to the same 
amount of DPPH reagent to overcome any inherent solvent activity. The reaction mixture was 
shaken well and allowed to stand at room temperature in the dark for 30 min, and then the 
decrease in absorbance at 517 nm was measured against a control (methanol solution) by using 
UV-vis spectrophotometer. The radical-scavenging activity of samples, expressed as percentage 
inhibition of DPPH (I %), and it was calculated according to the formula: 
 
% I = [(Acontrol-Asample) / Acontrol] X 100 
 
Where Acontrol is the absorbance of DPPH radical 
 
IC50 (concentration of the extract/compound producing 50% scavenging of DPPH radicals) was 
determined  using  non-linear  regression  analysis  of  the  dose-%I  relationship.  The  extract 
concentration  providing  50%  inhibition  (IC50)  was  calculated  from  the  graph  of  inhibition 
percentage plotted against extract concentration (100, 50, 25, 12.5, 6.25, 3.12, 1.56, 0.78 mg/ml). 
Antioxidant  capacities  of  the  extracts  were  compared  with  those  of  BHA,  gallic  acid  and 
ascorbic acid. Tests were carried out in triplicates. 
 
Data Analysis 
Tests were carried out were possible at least in duplicate on two different occasions. Results are 
reported as mean ± standard deviation (S.D.).  Standard curves were generated and calculation of 
the 50% inhibitory concentration (IC50) values was done using Excel. 
 
RESULTS:  
Forty seven plant species were selected based on their uses as remedies for the central nervous 
system diseases, as antidotes for human and animal poisoning or to improve memory and 
cognitive function (Table 1).  The inhibition effect of the 92 different extracts on AChE activity 
was screened using the Ellman’s method and the new micro-well plate AChE inhibition assay, 
NA-FB. 
The results obtained by Ellman’s method and the NA-FB assay of all plant extracts are 
shown in Table 1. The screenings were performed at a concentration of 100 mg/ml, and the 
extracts were considered as active if they only inhibited the enzyme >50%.  
Sixty two (67.4%) and 34 (37%) extracts inhibited AChE by > 50% using the NA-FB, and 
Ellman’s  assays,  respectively.  Also,  some  of  the  extracts  such  as  Salvia  fruticosa,  Galium 
pisiferum,  Anemone  coronaria,  Juglans  regia,  Ornithogalum  narbonense  and  the  leaves  of 
Asphodeline lutea, which had lower activity against AChE using Ellman’s method, exhibited 
much  higher  activity  using  the  NA-FB  (Figure  3).  Therefore,  AChEI  analysis  by  Ellman’s 
method was excluded from further discussion. Functional Foods in Health and Disease 2014; 4(9):381-400                                                            Page 388 of 400 
Table 1. Biological activities of Palestinian plants against different bioassays related to 
Alzheimer disease 
 
 
 
No.  Scientific name 
  
 Family Name 
Voucher 
No. 
Plant 
part  
AChEI 
on a 
scale of 
0-3 
% of Inhibition  IC50 (mg/ml) 
NA-FB  Ellman’s  DPPH  NA-FB  Ellman’s  DPPH 
1.    Allium neapolitanum Cirillo  Liliaceae  BERC-414  LE  2  63.4±2.26  6.21± 0.30  42.12±1.24  74.25  NA  NA 
2.          FL  2  55.96±1.47  58.04±1.19  53.26±1.78  99.4  44.3  6.16 
3.          ST  1  47.72±3.22  28.75±2.33  58.36±2.32  NA  NA  NA 
4.          BU  1  33.28±0.40  48.46±3.05  73.4±0.85  NA  NA  NA 
5.    Anemone coronaria L.  Ranunculaceae  BERC-355  FL  3  83.36±0.91  35.67±2.02  68.94±1.33  71.5  NA  1.7 
6.          LE  2  76.04±1.36  33.33±.33  76.73±1.03  71.5  NA  60.17 
7.    Asphodeline lutea (L.) Rchb. Liliaceae  BERC-371  LE  2  75±2.83  6.08±0.11  70.16±0.23  17.75  NA  100.21 
8.          BU  0  - 25.36±6.56  41.34±3.76  22.1±1.27  NA  NA  NA 
9.    Asphodelus aestivus Brot. 
(Asphodelus microcarpus 
Salzm. & Viv) 
Liliaceae  BERC-210  BU  1  49.7±0.42  4.64±0.91  53.55±2.05  NA  NA  NA 
10.      FL  0  - 6.42±0.82  1.73±0.38  25.3±0.99  NA  NA  NA 
11.    Bellevalia flexuosa Boiss.  Liliaceae  BERC-374  ST  1  51.27±5.28  2.47±0.75  14±1.41  97.3  NA  NA 
12.          LE  2  59.88±1.24  11.38±0.54  52.3±0.99  31.75  NA  12.76 
13.          BU  1  49.33±0.95  22.37±0.52  65.34±0.93  NA  NA  NA 
14.          FR  2  64.08±1.30  10.96±1.36  82.69±1.85  97.9  NA  2.14 
15.          FL  2  62.36±2.32  19.75±1.06  25.3±1.5  73.5  NA  NA 
16.   
Chrysanthemum coronarium 
L. 
Asteraceae 
BERC-068  LE  0  20.1±4.10  38.91±1.29  22.4±0.2  NA  NA  NA 
17.   
Conyza bonariensis 
Cronquist. 
Asteraceae 
BERC-259 
LE  2  70.1±2.69  81.23±2.50  65.25±1.06  2.89  54.8  2.74 
18.          FL  3  74.092±2.70  83.12±2.66  83.94±0.08  3.45  0.35  2.74 
19.     Dodonaea viscosa L.  Sapindaceae  BERC-045  LE  1  31.96±2.77  40.27±0.38  138.83±0.24  NA  NA  NA 
20.   
Erodium malacoides (l.) 
L'Her. 
Geraniaceae 
BERC-357  LE  0  - 4.10.57  33.69±0.98  70.5±0.71  NA  NA  NA 
21.          FL  0  - 7.51±0.69  1.11±1.26  74.25±1.06  NA  NA  NA 
22.    Eruca sativa Miller   Brassicaceae  BERC-202  LE  0  17.33±2.18  79.41±1.08  75.8±0.54  NA  36.7  NA 
23.    Euphorbia hierosolymitana 
Boiss. 
Euphorbiaceae  BERC-170  LE  0  10.29±1.00  19.75±1.06  93.07±0.10  NA  NA  NA 
24.        FL  0  11.38±0.88  29.81±1.15  99.33±1.88  NA  NA  NA 
25.    Foeniculum vulgare Mill.  Apiaceae  BERC-030  LE  3  89.81±1.03  52.68±0  72.12±0.76  3.5  99.3  27.54 
26.    Fumaria capreolata L.  Fumariaceae  BERC-367  FR  3  84.36±1.92  97.37±0.52  37.08±1.30  0.025  0.34  NA 
27.          LE  3  82.26±2.46  90.27±0.38  69±1.41  0.035  0.55  1.34 
28.          FL  3  85.25±1.06  98.14±1.61  76.41±0.83  0.921  2.1  0.514 
29.    Fumaria densiflora DC.  Fumariaceae  BERC-154  LE  3  79.78±0.31  83.12±0.17  56±1.41  0.62  21  0.51 
30.          FL  3  80.81±0.27  82.31±0.44  73.66±1.90  10.5  3.25  0.68 
31.    Fumaria vaillantii loisel   Fumariaceae  BERC-396  LE  3  81.17±1.17  95.98±1.39  67.25±0.35  10.5  5.75  1.4 
32.    Galium pisiferum Boiss.  Rubiaceae  BERC-038  FL  2  73.64±1.92  13.38±0.54  60.5±0.71  8.45  NA  24.16 
33.          LE  3  77.84±0.23  18.04 ± 0.06  81.58±0.59  10.45  NA  45.53 
34.   
Helichrysum sanguineum 
 (L.) Kostel.   
Asteraceae 
BERC-091 
LE  2  70.84±0.23  28.46 ±0.65  100±1.41  6.35  NA  44.5 
35.          FL  2  68.56±0.79  16.5±0.71  100±1.41  35.5  NA  53.5 
36.    Juglans regia L.   Juglandaceae    BERC-230  FR  3  78.562±2.39  11.36±1.50  78.69±0.20  8.52  NA  43.86 
37.    Lupinus pilosus L. 
(L. varius L.) 
Papilionaceae  BERC-019  FL  3  85.24±1.07  53.98±1.39  44.23±1.09  17.75  23.5  NA 
38.        LE  3  92.02±1.39  70.52±0.74  88.16±1.19  3.49  2.23  1.15 
39.          FR  1  23.13±0.034  44.93±1.5  71.26±0.27  NA  NA  NA 
40.   
Majorana syriaca  
(L.) Rafin. 
Lamiaceae 
BERC-026 
LE  2  70.58±0.59  88.1±1.98  100±1.3  2.9  9.5  0.21 
41.   
Mandragora autumnalis 
Bertol 
Solanaceae 
BERC-286 
FR  2  71.43±0.81  98.12±0.17  27.21±0.30  10.06  8.5  NA 
42.          RT  3  74.21±1.12  97.46±0.65  48.08±1.30  48.1  49  NA 
43.          LE  2  64.4±0.85  94.4±0.57  68.91±0.13  5.1  1.48  1.17 
44.   
   
 
FR(ri
pen) 
2  71.78±2.9  72.0±1.94  62.11±1.45  34.85  38.35  5.17 
45.  .  Mentha spicita L.   Labiatae    BERC-116  LE  3  94.8±1.93  74.17±0.176  93.52±0.33  6.3  36.35  0.56 Functional Foods in Health and Disease 2014; 4(9):381-400                                                            Page 389 of 400 
Table 1/ Cont. 
 
BU, Bulb, FL, Flower; FR, Fruit; LE, Leaves; SE, Seeds; ST, Stem; RT, Roots; NA, not applicable; ND, not determined 
 
 
No.  Scientific name 
  
 Family Name 
Voucher 
No. 
Plant 
part  
AChEI 
on a 
scale of 
0-3 
% of Inhibition  IC50 (mg/ml) 
NA-FB  Ellman’s  DPPH  NA-FB  Ellman’s  DPPH 
46.    Myrtus communis L.  Myrtaceae  BERC-051  LE  3  74.68±0.38  85.59±0.75  94.23±0.35  3.6  34.5  ND 
47.    Narcissus tazetta L.  Amaryllidaceae  BERC-395  BU  2  47.21±3.95  95.34±0.93  25.21±1.54  NA  NA  NA 
48.    Nigella sativa L.   Ranunculaceae   BERC-143  SE  2  73.58±0.38  92.49±0.38  88.08±0.35  69.5  7.75  3.62 
49.    Ophrys dinsmore Schltr  Orchidaceae  BERC-452  BU  1  44.6±1.98  20.96±1.36  17.6±0.57  NA  NA  NA 
50.          ST  2  59.12±1.24  32.88±1.24  70.67±0.95  89.5  NA  29.13 
51.          FL  2  62.08±1.30  39.79±1.12  85.19±1.15  30.5  NA  35.96 
52.          LE  2  73.12±2.66  25.58±0.82  143.33±2.36  12.1  NA  22.22 
53.    Ophrys lutea (Gouan) Cav  Orchidaceae  BERC-432  FL  3  75.8±0.28  51.75±1.06  64.32±0.96  94.21  91.2  11.75 
54.          ST  2  53.36±0.51  31.33±0.47  88.3±0.99  26.5  NA  46.4 
55.          LE  2  72±1.41  54.5±0.71  94.23±1.09  97.12  95.6  5.08 
56.    Orchis caspia Trautv  Orchidaceae  BERC-422  ST  2  68.76±1.75  27.75±1.06  79.32±0.96  47.4  NA  57.88 
57.          LE  3  88.88±1.58  97.61±0.86  81.75±0.35  5.7  6.75  0.51 
58.          FL  2  61.52±2.09  43.79±1.12  87.21±1.12  97.8  NA  2.74 
59.    Orchis collina Banks &Sol.  Orchidaceae  BERC-448  BU  0  24.48±2.15  26.5±0.71  10.19±1.15  NA  NA  NA 
60.          ST  2  57.44±0.79  23.04±0.06  55.61±0.55  98.4  NA  3.2 
61.          LE  2  69.08±1.30  38.33±0.95  85.38±2.29  21.85  NA  70.81 
62.          FL  2  61.36±0.91  33.25±0.35  91.41±0.83  11.5  NA  19.67 
63.    Ornithogalum narbonense 
L. 
Liliaceae  BERC-464  BU  1  38.64±1.92  - 5.67 ± 0 .95  54.71±0.41  NA  NA  NA 
64.        FL  2  69.2±0.28  - 0.33 ± 0 .95  46.25±1.06  92.5  NA  NA 
65.          ST  2  66.24±1.07  17.21  ± 1.12  67±1.41  78.63  NA  86.32 
66.          LE  3  75.88±0.17  -3.71 ± 1.00  80.86±1.22  25.9  NA  21.81 
67.    Oxalis pes-caprae L.  Oxalidaceae  BERC-265  FL  2  74.33±0.95  100.22±0.31  110.75±1.06  ND  ND  ND 
68.          LE  3  89.21±0.35  88.26±0.37  147.43±0.61  6.5  23.3  1.3 
69.    Parietaria judaica L.  Urticaceae  BERC-063  LE  2  71.19±1.15  31.91±1.29  71.66±0.93  70.3  NA  ND 
70.    Peganum harmala L.  Zygophyllaceae   BERC-181  SE  2  50.85±0.21  81.06±0.08  80.12±0.15  5.81  ND  3.1 
71.   
Pelargonium  
odoratissimum (L.) L 'He'r 
Geraniaceae 
BERC-049 
LE  0  - 15.44±0.79  - 1.58±1.24  88.91±0.13  NA  NA  NA 
72.    Phagnalon rupestre (L.) 
DC. 
Asteraceae  BERC-047  FL  3  80.5±2.12  93.24±0.34  57±0.00  6.25  8.5  0.93 
73.        LE  3  81.1±2.69  95.61±0.86  150.2±.036  10.2  7.1  1.9 
74.    Ranunculus asiaticus L.  Ranunculaceae  BERC-400  FL  2  71.67±0.47  88.47±0.66  45.75±0.35  14.3  11.54  NA 
75.    Ranunculus millefolius 
Banks & sol. 
Ranunculaceae  BERC-475  LE  1  31.23±2.50  76.75±1.06  57.58±0.82  ND  65.8  2.25 
76.        FL  0  22.64±1.92  17.33 ± 0 .47  64.61±0.55  ND  ND  ND 
77.    Raphanus rostratus DC.  Cruciferae  BERC-368  LE  1  28.12±1.24  24.1±1.27  81.75±0.35  ND  ND  ND 
78.    Retama raetam (Forssk.) 
Webb 
Salvadoraceae  BERC-043  FL  2  69.25±1.77  29.59±0.83  51.5±0.71  85.83  ND  60.2 
79.        LE  0  21.85±1.63  16.62±3.37  59.58±0.59  NA  NA  NA 
80.    Rosmarinus officinalis L.  Labiatae  BERC-018  LE  3  76.39±0.86  95.32±0.45  99.16±1.19  2.4  14.8  0.38 
81.    Salvia fruticosa (L.) Mill.   Labiatae  BERC-006  LE  3  85.68±1.26  46.81±2.26  73.1±0.97  4.45  NA  33.08 
82.    Scorzonera papposa L.  Asteraceae  BERC-401  FL  1  41.08±1.30  17.33 ± 0 .47  44.8±1.13  NA  NA  NA 
83.          LE  1  48.24±2.49  15.83  ± 0.24  49.03±1.37  NA  NA  NA 
84.    Smyrnium olusatrum L.  Apiaceae  BERC-416  LE  0  3.09±8.61  5.01±1.98  57.83±1.17  NA  NA  NA 
85.          FL  1  26.21±1.12  3.98±1.39  82.41±0.83  NA  NA  NA 
86.    Tulipa sharonensis Dinsm.  Liliaceae  BERC-431  LE  1  52.3±2.40  56.5±0.71  38.08±1.30  44.5  26.5  ND 
87.          ST  1  41.08±2.72  50.79±0.30  61.9±0.14  ND  48.3  20.38 
88.          FL  2  56.88±0.17  37.42±0.82  64.41±0.58  37.5  NA  24.62 
89.          BU  1  46.12±1.24  - 18.63±0.89  71.82±0.25  NA  NA  NA 
90.    Urtica pilulifera L.  Urticaceae   BERC-066  LE  2  58.6±2.4  2.73±0.77  86.66±0.96  10.25  NA  38.32 
91.    Vicia hybrida L.  Papilionaceae  BERC-420  LE  3  74.27±1.03  49.96±1.36  41.05±1.34  50.23  NA  NA 
92.    Zingiber officinale  Rose.  Zingiberaceae   BERC-501  BU  1  41.25±1.06  48.04±0.06  99±1.2  NA  NA  NA 
  Galanthamin      NA  3  88.8±1.13  93.44±2.21  NA  0.015  0.02  NA 
  Ascorbic acid                    0.07 
  BHA                    0.009 
  Gallic acid                     0.033 Functional Foods in Health and Disease 2014; 4(9):381-400                                                            Page 390 of 400 
 
 
Figure  3.  Categories  of  AChE  inhibitory  activities  based  on  Ellman’s  and  NA-FB  AChE 
inhibition assays 
 
The new method produced colorimetric change better observable visually over the  Ellman’s, 
allowing quantitative as well as qualitative assay, and did not show any chemical reactivity with 
thiol used for the Ellman’s method, therefore avoid false positive reaction of enzyme activity 
provided by samples containing thiol-bearing molecules (e.g., Bellevalia flexuosa). Qualitative 
determination of AChE inhibitory activity using the NA-FB method revealed that 66.3 % (61 
extracts) of the plant extracts showed moderate to high AChE activity, 19.6 % (18) showed low 
activity, and 14.1% (13) were not active (Figure 4).  
 
 
 
Figure 4. Qualitative determination of AChE inhibitory activities based on the NA-FB AChE 
inhibition assay Functional Foods in Health and Disease 2014; 4(9):381-400                                                            Page 391 of 400 
Extracts  from  the  leaves  of  Pelargonium  odoratissimum,  and  bulb  of  Asphodeline  lutea. 
activated AChE more than 15% and 25 %, respectively (Figure 5). The most potent extracts 
using the modified method were Mentha spicata (94.8 %), Lupinus pilosus (92.02), Foeniculum 
vulgare (89.81), Oxalis pes-caprae (89.21), and Orchis caspia (88.88) (Figure 5).  
The dose-dependent AChE inhibitory activity of the active herbs was further studied, and 
the IC50 values of inhibition are presented in Table 1. Ethanol extracts of the tested plants were 
found to have high AChE inhibitory activities in a dose-dependent manner.  Further testing and 
analyses  of  the  inhibition  of  AChE  by  leaves  of  Fumaria  capreolata,  Fumaria  densiflora, 
Rosmarinus  officinalis,  Conyza  bonariensis,  and  Majorana  syriaca  revealed  IC50  values  of 
0.035, 0.62, 2.4, 2.9, and 2.9 mg/ml, respectively. 
 
 
 
Figure 5.  % inhibition of AChE by different plant extracts at 100 mg/ml. G, Galanthamine. 
Plant extract numbers on X axis as in Table 1. 
 
The inhibition type of plant extracts which showed > 50% inhibition activity was determined 
by assaying the change in the remaining AChE activity of the mixture of AChE and the plant 
extract  before and after the dilution of the plant extract  in  the same mixture. While, AChE 
activity was restored more than 5 fold by 10 times dilution of Juglans regia, Oxalis pes-carpae, 
and  Foeniculum  vulagare,  the  same  dilution  of  Fumaria  capreolata,  F.  densiflora,  Lupinus 
pilosus,  Peganum  harmala  and  Mandragora  autumnalis  did  not  show  any  effect  on  the 
remaining activity of AChE after dilution. This result indicates that AChE is inhibited reversibly 
by Juglan regia, Oxalis pes-carpae, and Foeniculum vulagare and irreversibly by the leaves, 
flowers,  and  fruits  of  F.  capreolata,  the  leaves  and  flowers  of  F.  densiflora,  the  seeds  of 
Peganum harmala, and the leaves of Lupinus pilosus and Mandragora autumnalis. Functional Foods in Health and Disease 2014; 4(9):381-400                                                            Page 392 of 400 
Table 1 shows the antioxidant results of the tested plant extracts. Seventy-three extracts 
showed > 50% antioxidant activity, of these Phagnalon rupestre, Oxalis pes-caprae, Ophrys 
dinsmor, Dodonaea viscosa, Helichrysum  sanguineum, and Majorana syriaca were the most 
active. The IC50 of the antioxidant activity for the plants extracts, which showed > 50 % AChE 
inhibition activity using the NA-FB was determined (Table 1). Of these eight extracts; leaves of 
M.  syriaca  (IC50  0.212mg/ml),  leaves  of  Rosmarinus  officinalis  (0.377  mg/ml),  leaves  of 
Fumaria densiflora (0.514 mg/ml), leaves  of  Orchis caspia  (0.514 mg/ml), leaves of Mentha 
apicata  (0.56  mg/ml)  flowers  of  Fumaria  densiflora  (0.678  mg/ml),  flowers  of  Fumaria 
capreolata (0.69 mg/ml), and flowers of Phagnalon rupestre (0.928 mg/ml) were particularly 
strong antioxidants when compared to the reference radical scavengers (BHA, gallic acid, and 
ascorbic acid) recording IC50’s < 1 mg/ml.  
 
DISCUSSION:  
Palestine is enriched with great plant diversity, and 368 of these plants have been reported to be 
used in TAPHM for the treatment of several diseases [40]. However, the use of medicinal plants 
is  mainly  based  on  local  tradition  and  not  scientific  knowledge  [41-43].  The  chemical 
constituents of most of these plants are unknown and may have dangerous effects on human 
health.  On the other hand, some plants, which are not reported to be used in herbal medicine, 
might also possess potential activity.  
The  deficiency  of  ACh  is  one  of  characteristics  of  AD  and  responsible  for  most  of  its 
symptoms,  such  as  a  decline  in  memory  and  cognition.  AChE  inhibitors  such  as  tacrine, 
donepezil, rivastigmine, and galantamine are currently used as anti-AD drugs [44]. The side 
effects  of  these  anti-AChE  drugs,  such  as  toxicity,  tolerability,  and  loss  of  efficiency,  have 
interested the researchers to consider alternative natural anti-AD substances in place of current 
synthetic medications [45]. 
In  the  present  work,  the  selected  extracts  were  screened  for  AChE  inhibition  using  the 
Ellman’s method and the NA-FB assay at 100 mg/ml dose. The Ellman’s method is the most 
widely used AChE inhibitory assay [32]. This method has some advantages and disadvantages. 
Its main advantages are simplicity, rapid processing of large numbers of samples, fast conversion 
of ACTI comparing to other artificial substrates such as naphthyle acetate and relatively low cost 
[46, 47]. On the other hand, Ellman’s method has some disadvantages, including the interference 
of some compounds. The -SH groups in the plant extract may react with DTNB and ATCh, thus 
the natural substrates are not identical from a kinetic point of view. False positive reaction of 
enzyme activity can be provided by samples containing a lot of thiol-bearing molecules.   
To overcome this problem an alternative method using β-naphthyl acetate as the substrate 
and fast blue B as the color reagent (absorbance at 600 nm) instead of DTNB was developed in 
this  study.  The  main  advantages  of  this  method  is  that  the  colorimetric  change  is  better 
observable visually, allowing spectrophotometric as well as colorimetric assay, and does not 
show  any  chemical  reactivity  with  thiol,  therefore  avoid  false  positive  reaction  of  enzyme 
activity provided by samples containing thiol-bearing molecules. The NA-FB method can be 
considered superior and more sensitive than the Ellman’s assay. In the present study, 67.4% of 
plant extracts inhibited AChE by > 50% using the NA-FB method, while only 37% extracts 
inhibited AChE by > 50% using Ellman’s assay. This result can be attributed to the accuracy and Functional Foods in Health and Disease 2014; 4(9):381-400                                                            Page 393 of 400 
stability of the reaction using naphthyle acetate. Naphthyle acetate splits with lower turnover 
rate, and does not show any chemical reactivity with thiol used for the Ellman’s method [37], 
thus NA-FB can be advantageously used for accurate measurements of AChE activity. 
Sixty two extracts belonging to 34 plant species (Table 1) have been identified to effectively 
inhibit  AChE  enzymes,  which  is  considered  to  be  related  to  the  mechanism  of  memory 
dysfunction in this study. In the light of these findings, we can conclude that most of the plant 
extracts screened showed inhibitory activity against AChE and could be considered worthwhile 
in  future  studies  in  the  treatment  of  AD.  In  particular,  the  species  belonging  to  Apiaceae, 
Papilionaceae,  Oxalidaceae,  Orchidaceae,  Lamiaceae,  Fumariaceae  families  had  the  highest 
activity ranging between 94.8 and 85.25% at 100 mg/ml concentration against AChE. Since most 
of the AChE inhibitors are known to contain nitrogen, the higher activity of these extracts may 
be due to their rich alkaloidal content [9]. 
The  most  potent  extracts  were  the  leaves  of  Fumaria  capreolata,  Fumaria  densiflora, 
Rosmarinus officinalis, Conyza bonariensis, and Majorana syriaca with IC50 values of 0.035, 
0.62, 2.4, 2.9, and 2.9 mg/ml respectively. At a concentration of 100 mg mL–1, they reduced the 
enzymatic activity of AChE to 17.74%, 20.22, 23.61, 29.9 and 29.42 respectively. The inhibition 
type of AChE varied among plant extracts, while 84 extracts showed reversible inhibition, 8 
showed  irreversible  inhibitions.  Although  IC50  values  of  Fumaria  capreolata,  Fumaria 
densiflora, are higher than that of Rosmarinus officinalis and Majorana syriaca, the inhibition 
type in this study showed that Rosmarinus officinalis and Majorana syriaca reversibly inhibits 
AChE and can be used for AD’s medication rather than Fumaria capreolata, F. densiflora which 
inhibits  irreversibly  AChE.  This  recommendation  was  supported  by  the  toxicity  reports  in 
literature which indicated the higher safety margin of R. officinalis and M. syriaca as compared 
to Fumaria species. 
Rosmarinus  officinalis  (rosemary)  contains  the natural  COX‑2 inhibitors  (e.g.  Apigenin, 
carvacrol,  eugenol,  oleanolic  acid,  thymol,  and  ursolic  acid,  which  can  prevent  Alzheimer’s 
disease [48] . In addition, rosemary contains antioxidants and anti‑inflammatory compounds. 
Some of the strongest antioxidant substances in the plant are carnosic acid and ferulic acid, 
which have been reported to posses antioxidant activity much higher than the widely common 
synthetic antioxidants butylated hydroxytoluene (BHT) and butylated hydroxyanisole (BHA) [3].  
Conyza bonariensis is a medicinal plant, which has been reported to be used for constipation 
and diarrhea, has been attributed to the spasmogenic and spasmolytic constitute of the plant [49]. 
The leaves and flowers of the plants have shown to possess high AChEI activity > 70% with IC50 
value ranging between 2.89-3.45 mg/ml.  
Majorana syriaca possesses an important food-flavouring ingredient in the Middle Eastern 
culture, known commonly as Za'atar. The plant is used traditionally for the treatment of several 
ailments and is associated as memory enhancer [2]. The main components of the plant extract 
according to GS-MS analysis were thymol, and carvacrol. The remaining compounds comprise 
flavonoids and phenolic acids that provide the antiradical and antioxidant activity [50]. The plant 
has shown to have strong activity against AChE, ursolic acid which has been isolated from the 
plant, has shown to be a potent AChE inhibitor in Alzheimer's Disease [51]. Functional Foods in Health and Disease 2014; 4(9):381-400                                                            Page 394 of 400 
Fumaria  species  have  been  used  in  traditional  medicine  as  antihypertensives,  diuretics, 
hepatoprotectants and laxatives (to treat gastrointestinal disorders), as well as in the treatment of 
rachis and conjunctivitis [52]. The plant has also been evaluated pharmacologically and shown to 
possess antihelmintic, antipyretic and hypoglycemic properties [53-55]. The biological activities 
of Fumaria species have been mainly associated with the presence of isoquinoline alkaloids [56]. 
The toxicity of the species have been evaluated, Fumaria capreolata has shown to be non-toxic 
[56], while F. densiflora was reported to be toxic [57]. The AChEI activity of Fumaria species 
has been reported by several researchers; the plant was reported to have strong AChEI activity 
[9]. In this study, Fumaria were among the most active plant extracts against AChE activity, 
however,  the  reaction  was  shown  to  be  irreversible,  thus  the  plant  cannot  be  used  for  the 
treatment of AD as the activity of the enzyme cannot be restored. 
AChEI activity of the methanolic extract of Peganum harmala, has previously been reported 
by Ali et al. [26]. The  plant contains β-carboline alkaloids, which demonstrated potent activity 
against AChE [58]. Harmaline, the major active constituent of P. harmala, is a common dihydro 
β-carboline type; it possess interesting pharmacological activities and can  interact with several 
enzymes and neurotransmitters including topoisomerase I, and monoamine oxidase-A [59, 60].  
Although,  P.  harmala  has  been  used  in  traditional  medicine,  there  are  reports  of  severe 
intoxication in cattle, donkeys, sheep and horses [61]. Digestive and nervous syndromes have 
been reported in animals that consume a sub-lethal amount of the plant. Harmaline and harmine 
are toxic alkaloids characterized in the seeds of P. harmala. Harmaline is almost twice as toxic 
as harmine and in moderate doses cause tremors and clonic convulsions, but with no increase in 
spinal reflex excitability [62]. The seeds of P. harmala were among the potent  plant extracts 
against AChE activity, however, the reaction  have been shown to be irreversible, thus the plant 
cannot be used for the treatment of AD. 
Some insecticides including organophosphate and carbamates cause AChEI which lead to 
the  accumulation  of  ACh  at  neuromuscular  junctions  causing  rapid  twitching  of  voluntary 
muscles and eventually paralysis of the insects. However, in this study, leaves and flowers of 
Fumaria  species,  seeds  of  P.  harmala,  and  the  leaves  of  Lupinus  pilosus  and  Mandragora 
autumnalis, which have shown high irreversible AChEI activity, can be considered potent natural 
insecticides.  
Alzheimer’s appears to be caused to a large degree by oxidative damage [63]. Therefore, 
antioxidants, in general, should have positive effects in both the prevention and treatment of 
Alzheimer’s. A study found that antioxidants such as vitamin A, vitamin D, lycopene, and beta 
carotene were all significantly lower in Alzheimer’s disease patients compared to controls [64]. 
Another  study  of  633  patients  aged  >  65  years  found  that  high  dose  supplementation  with 
vitamin  C  decreased  the  risk  of  developing  AD  [65].  Therefore,  the  plant  extracts  which 
demonstrated  potent  free  radical  scavenging  properties  are  expected  to  play  a  vital  role  in 
reducing  the  oxidative  stress  and  this  may  explain  their  use  in  traditional  medicine  for 
improvement of AD and/or ageing related diseases.  It’s worth mentioning that some of the plant 
extracts which have high antioxidant activity including  M. spicata (93.52), Z. officinale (99), R. 
officinalis (99.16), M. syriaca (100), and the leaves  of O. pes-caprae (147.43), are wild edible 
plants widely consumed  among the Palestinian population [66]. Some of these plants have been 
reported to be used traditionally for memory enhancement [2, 3, 23, 66].  Functional Foods in Health and Disease 2014; 4(9):381-400                                                            Page 395 of 400 
CONCLUSION: 
The  new  micro-well  plate  AChE  activity  assay  (NA-FB)  has  shown  to  be  simple,  accurate, 
sensitive,  spectrophotometric  and  colorimetric,  and  superior  to  the  Ellman’s  method,  and 
therefore  can  be  used  efficiently  for  qualitative  and  quantitative  studies  of  AChE  inhibitory 
activities of plant extracts of a wide range of diverse plant species and to give high detection 
rates from a range of plant parts. The extracts of R. officinalis, M. spicata, M. syriaca, and N. 
sativa were proved to have a great potential and should be considered for further studies to 
identify the constituents responsible for the AChE inhibitory activity, which can be eventually 
utilized in the prevention and treatment of AD.  
The pathophysiological process of AD is thought to begin many years before the diagnosis 
of AD dementia. This long "preclinical" phase of AD would provide an important opportunity 
for therapeutic intervention.  It  is  hoped  that  plants  with  strong reversible  AChEI and  strong 
antioxidant  activities  will  aid  in  earlier  intervention  at  a  stage  of  AD  when  some  disease-
modifying therapies may be most efficacious. 
 
List of abbreviations: 
TAPHM   Traditional Arabic Palestinian Herbal Medicine   
AD     Alzheimer’s disease  
ACh     acetylcholine  
AChE    acetylcholinesterase  
AChEIs   AChE inhibitors  
ACTI    acetylthiocholine iodide  
DTNB     5,5’-dithio-bis-2-nitrobenzoic acid  
BSA     bovine serum albumin  
DPPH    diphenyl-1-picrylhydrazyl  
BHA     Butylated hydroxyanisole   
NA-FB   New Micro-Well Plate AChE Inhibition Assay  
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